Pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the treatment of the first-line treatment of metastatic squamous non-small cell lung carcinoma.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||25/02/2019|
|Rapid review completed||25/03/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with carboplatin and either paclitaxel or nab-P compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.
The HSE has approved reimbursement following confidential price negotiations – February 2021.